1. Scrip
  2. >>Focus On Asia
  3. >>Japan

Shake It Off? Japan Mulls Routes Out Of Bioventure Doldrums

Nurturing, Translational Research Hopes Aired At BioJapan

 
• By Ian Haydock

The long-recurring theme of how effectively to foster Japan’s bioventure sector again emerged as a key thread at recent major industry meeting, while the broader topic of effective partnering occupied the minds of industry and academia alike.

Yokohama
Yokohama Meeting Hears Challenges, Responses • Source: Shutterstock

Japan’s bioventure sector seems to have been in an “emerging” state for decades. While there are now hundreds of home-grown companies in the therapeutics space, only a handful have reached the commercial stage and any substantial size, while post-IPO valuations have in many cases struggled.

The major challenges are well-documented - lack of venture capital funding, aversion to investment and development risk and failure, long...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

Multiple Factors Driving Japan’s Pioneering Angiosarcoma Pipeline

 
• By Lisa Takagi

Japan has emerged as a global leader in the development of new drugs for the rare cancer angiosarcoma, reflecting its rapidly ageing population and the limitations of current therapies.

China Sentences Astellas Employee To 3.5 Years In Prison On Spy Charges

 
• By Lisa Takagi

An employee of Astellas faces three and a half years in prison after sentencing by a court in China on espionage charges.

Activist Investor Vs. Japan Pharma: ASKA Plans Poison Pill As Dalton Pushes For MBO

 
• By Lisa Takagi

While ASKA plans to dilute the holding of largest investor Dalton by issuing new shares, the US investment firm continues to push a management buyout option to the mid-sized Japanese pharma company.

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By Lisa Takagi

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

More from Focus On Asia

Dr Reddy’s On Semaglutide Prospects, Capacity And There’s An IP Hearing To Watch

 
• By Anju Ghangurde

Dr Reddy’s CEO discusses the growth opportunity for semaglutide, including production capacity and ‘crazy’ demand indications, and a potential 20-plus product GLP-1 portfolio. All eyes are also on an upcoming hearing in India pertaining to Novo Nordisk’s semaglutide patent in the country.

GSK Gains Hengrui’s PDE3/4 Inhibitor, Options For 11 Early Assets In Potential $12bn Deal

 
• By Dexter Jie Yan

Deal Snapshot: The addition of Hengrui's HRS-9821, a China-originated fast-follower of Verona’s Ohtuvayre in chronic obstructive pulmonary disease, should enable GSK’s COPD therapy portfolio to stack up well against increasing competitors in the indication, including biologics and small molecules.

Korean Biopharma Catching Up On AI, But What Are The Challenges?

 
• By Jung Won Shin

While South Korea's biopharma sector has made progress in its digital transformation, including the adoption of AI technologies, a recent report has identified multiple remaining challenges.